文献速递神经创伤神经重症

未用Andexanet逆转的Xa抑制剂相关创伤性颅内出血进展风险低

Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
PubMed 文献 · World Neurosurg · 2020-06-17

单中心2016—2019年回顾性队列纳入伤前18小时内使用阿哌沙班或利伐沙班的创伤性颅内出血患者,均未使用Andexanet alfa。

要点

  • 伤前使用Xa抑制剂的重型轻型TBI患者,未用Andexanet时血肿进展率低。
  • 多数患者采用4因子凝血酶原复合物尝试逆转抗凝。
  • 重复影像止血结局与文献报道的Andexanet给药后结局相似。

核心结论

  • 伤前使用Xa抑制剂的复杂性轻型TBI患者,未使用Andexanet alfa时颅内出血进展率与未抗凝或使用可逆抗凝剂者相似。
  • 本队列止血结局与Andexanet alfa给药后报道的结局相似。

研究设计与样本

  • 单中心2016—2019年回顾性队列研究,查询机构TBI登记数据库。
  • 纳入伤前18小时内记录使用阿哌沙班或利伐沙班的患者。
  • 共识别25例符合纳入标准患者,2例因缺乏必要CT数据被排除。

主要发现

  • 入院CT示14例硬膜下血肿、6例创伤性实质内出血、3例蛛网膜下腔出血。
  • 17例(74%)尝试抗凝逆转,主要使用4因子凝血酶原复合物。
  • 20例(87%)重复影像判定为止血优良或良好。

关键数值与推荐

  • 主要结局为重复头颅CT血肿体积或厚度增加<35%。

临床怎么用

  • 对伤前使用Xa抑制剂的复杂性轻型TBI患者,未用Andexanet时血肿进展风险较低。
  • 可采用4因子凝血酶原复合物等策略尝试逆转,并结合重复影像评估止血效果。

局限性

  • 未设未抗凝或Andexanet对照臂,结论基于与历史报道的比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Andexanet alfa, a novel anticoagulation reversal agent for factor Xa inhibitors, was recently approved. Traumatic intracranial hemorrhage presents a prime target for this drug. The Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors study established the efficacy of andexanet alfa in reversing factor Xa inhibitors. However, the association between anticoagulation reversal and traumatic intracranial hemorrhage progression is not well understood. The objective of this study was to determine progression rates of patients with traumatic intracranial hemorrhage on factor Xa inhibitors prior to hospitalization who were managed without the use of andexanet alfa. METHODS: A retrospective cohort study was performed between 2016 and 2019 at a single institution. An institutional traumatic brain injury (TBI) registry was queried. Patients with recorded use of apixaban or rivaroxaban <18 hours before injury were included. The primary study outcome was <35% increase in hemorrhage volume or thickness on repeated head computed tomography (CT) scans. RESULTS: We identified 25 patients meeting the inclusion criteria. Two patients were excluded because of a lack of necessary CT data. Twelve patients (52%) were receiving apixaban, and 11 were (48%) on rivaroxaban. On admission CT scan, 14 patients had subdural hematoma, 6 had traumatic intraparenchymal hemorrhage, and 3 had subarachnoid hemorrhage. Anticoagulation reversal was attempted in 17 patients (74%), primarily using 4-factor prothrombin complex concentrate. Twenty patients (87%) were adjudicated as having excellent or good hemostasis on repeat imaging. CONCLUSIONS: Our results indicate that patients on factor Xa inhibitors with complicated mild TBI have a similar intracranial hemorrhage progression rate to patients who are not anticoagulated or anticoagulated with a reversible agent. The hemostatic outcomes in our cohort were similar to those reported after andexanet alfa administration.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Maragkos GA, Nelton EB, Richter S, et al. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal. World Neurosurg. 2020. PMID: 32561488. doi:10.1016/j.wneu.2020.06.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。